Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1512796 | 0.82 | PIM1 (0.41) | ESR1ESR2ARPIM1ADRA2A | |
| SCHEMBL1425995 | 0.82 | NOTUM (0.31) | — | |
| SCHEMBL29987655 | 0.82 | PIM1 (0.41) | ESR1ESR2ARPIM1ADRA2A | |
| SCHEMBL29559941 | 0.82 | NOTUM (0.31) | — | |
| SCHEMBL8265461 | 0.76 | — | — | |
| SCHEMBL23118208 | 0.72 | TTR (0.33) | — | |
| SCHEMBL423158 | 0.72 | AR (0.37) | ESR1ESR2AR | |
| SCHEMBL24133089 | 0.72 | TYR (0.32) | ADRB2 | |
| SCHEMBL155976 | 0.71 | CES2 (0.46) | ESR1ESR2ARPIM1 | |
| SCHEMBL31070217 | 0.71 | CES2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6100484-A | — | — | None | — | — | JP | disclosed |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| CN-113549065-B | Pyrrolo [2,3-b ] pyridine derivatives as JAK inhibitors | 成都先导药物开发股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-108203584-B | Compound, liquid crystal composition and application thereof | 江苏和成显示科技有限公司 | 2021-11-23 | — | — | CN | disclosed |
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-9714231-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-25 | — | — | US | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| EP-2925741-B1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160280680-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-09-29 | — | — | US | disclosed |
| EP-2576527-B1 | HETEROCYCLIC ALKANOL DERIVATIVES AS FUNGICIDES | BAYER IP GMBH (DE) | 2016-01-20 | — | — | EP | disclosed |
| US-20120004101-A1 | Novel Heterocyclic Alkanol Derivatives | BAYER CROPSCIENCE AG (DE) | 2012-01-05 | — | — | US | disclosed |
| WO-2011147816-A1 | HETEROCYCLIC ALKANOL DERIVATIVES AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2011-12-01 | — | — | WO | disclosed |
| US-6703082-B1 | VARIOUS NAPHTHALENE-CONTAINING LIQUID CRYSTALS | DISPLAYTECH, INC. | 2004-03-09 | — | — | US | disclosed |
| US-6413448-B1 | ESTERS; DOPANTS; LONGER CHIRAL SMECTIC PHASE PITCH; HIGHER TILT ANGLE; LOWER VISCOSITY; CRYSTALLIZATION SUPPRESSION; IMPROVED SOLUBILITY; BROADER C* PHASE TEMPERATURE RANGE | DISPLAYTECH, INC. | 2002-07-02 | — | — | US | disclosed |
| WO-2000065801-A9 | CYCLOHEXYL- AND CYCLOHEXENYL-SUBSTITUTED LIQUID CRYSTALS WITH LOW BIREFRINGENCE | DISPLAYTECH INC (US) | 2001-04-12 | — | — | WO | disclosed |
| WO-2000065801-A1 | CYCLOHEXYL- AND CYCLOHEXENYL-SUBSTITUTED LIQUID CRYSTALS WITH LOW BIREFRINGENCE | DISPLAYTECH, INC. (US) | 2000-11-02 | — | — | WO | disclosed |
| JP-H06100484-A | IODINATED PHENOLIC COMPOUND AND ITS PRODUCTION | SANYO CHEM IND LTD | 1994-04-12 | — | — | JP | disclosed |
| EP-0518636-A1 | Liquid crystal compounds and compositions | SANYO CHEMICAL INDUSTRIES LTD. (JP) | 1992-12-16 | — | — | EP | disclosed |
| EP-0517498-A1 | Liquid crystal compounds and compositions | SANYO CHEMICAL INDUSTRIES LTD. (JP) | 1992-12-09 | — | — | EP | disclosed |
| EP-0500210-A2 | Liquid crystal compounds and compositions | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 1992-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004101-A1 | Novel Heterocyclic Alkanol Derivatives | ERG28, CBR3, MYB | ESR1 3579/4885ESR2 3333/4885AR 3051/4885 |
| US-20160280680-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR27 | ESR1 518/4885ESR2 525/4885AR 392/4885 |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | ESR1 3453/4885ESR2 941/4885AR 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.